Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.

Katayama, Ryohei

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Nov 2014 - 5686-96 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1557-3265

10.1158/1078-0432.CCR-14-1511 doi


Anaplastic Lymphoma Kinase
Benzoquinones--pharmacology
Carbazoles--pharmacology
Carcinoma, Non-Small-Cell Lung--diagnostic imaging
Cell Line, Tumor
Crizotinib
DNA Mutational Analysis
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm--genetics
HSP90 Heat-Shock Proteins--antagonists & inhibitors
Humans
Inhibitory Concentration 50
Lactams, Macrocyclic--pharmacology
Lung Neoplasms--diagnostic imaging
Models, Molecular
Mutation
Piperidines--pharmacology
Protein Conformation
Protein Kinase Inhibitors--pharmacology
Pyrazoles--pharmacology
Pyridines--pharmacology
Receptor Protein-Tyrosine Kinases--antagonists & inhibitors
Tomography, X-Ray Computed